UNITEDTable STATES SECURITIESof AND EXCHANGE COMMISSION Contents

~~Washington,~~UNITED ~~D.C.~~STATES SECURITIES ~~20549~~AND EXCHANGE COMMISSION

~~FORM~~Washington, ~~8-K~~D.C. 20549

~~CURRENT~~FORM ~~REPORT~~8-K ~~Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934~~

~~Date~~CURRENT ofREPORT Pursuant ~~Report~~to Section 13 or 15(~~Date~~d) of ~~earliest~~the Securities ~~event~~Exchange ~~reported):~~Act ~~September 28,~~of ~~2007~~1934

~~Artes~~ Date ~~Medical~~of Report (Date of earliest event reported): July 7, ~~Inc.~~2008

~~(Exact~~Artes ~~Name~~Medical, ~~of Registrant as Specified in Charter)~~Inc.

Delaware		001-33205		33-0870808
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

(Exact Name of Registrant as Specified in Charter)

~~5870~~Delaware ~~Pacific~~(State ~~Center~~or ~~Boulevard San~~Other ~~Diego,~~Jurisdiction ~~California~~of ~~92121~~ Incorporation) 001-33205 (Commission File Number) 33-0870808 (I.R.S. Employer Identification No.)

5870 Pacific Center Boulevard San Diego, California 92121 (Address of Principal Executive Offices, with zip code)

(858) 550-9999 (Registrant’s telephone number, including area code)

n/a (~~Registrant’s~~Former ~~telephone~~Name ~~number~~or Former Address, ~~including~~if ~~area~~Changed ~~code~~Since Last Report)

~~n/a~~Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (~~Former~~17 ~~Name~~CFR or230.425) ~~Former~~o ~~Address,~~Soliciting ifmaterial ~~Changed~~pursuant ~~Since~~to ~~Last~~Rule ~~Report~~14a-12 under the Exchange Act (17 CFR 240.14a-12) o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

~~Check~~TABLE ~~the~~OF ~~appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):~~ CONTENTS

oItem ~~Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230~~1.~~425)~~01 oEntry ~~Soliciting~~into ~~material~~a ~~pursuant~~Material toDefinitive ~~Rule~~Agreement ~~14a-12~~Item ~~under the Exchange Act (17 CFR 240~~9.~~14a-12) o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240~~01.~~14d-2(b))~~ oFinancial ~~Pre-commencement~~Statements ~~communications~~and ~~pursuant~~Exhibits toSIGNATURE ~~Rule~~EXHIBIT ~~13e-4(c) under the Exchange Act (17 CFR 240~~99.~~13e-4(c))~~1

Item 5.02.Table Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Contents

OnItem ~~September 28, 2007, Daren Barone resigned from the Board of Directors (the “Board”) of Artes Medical, Inc~~1.01 ~~(the~~Entry ~~“Company”).~~into ~~The resignation of Mr. Barone from the Board did not involve any disagreement with the Company. At the time of his resignation, Mr. Barone was~~ a ~~member~~Material ofDefinitive ~~the Board’s Audit Committee, Nominating/Corporate Governance Committee (“Nominating Committee”) and Compensation Committee~~Agreement.

AtOn ~~the~~July 7, ~~Nominating~~2008, ~~Committee’s~~we ~~recommendation,~~entered into a Distribution Agreement (the ~~Board~~“Agreement”) ~~elected~~with ~~Beverly~~Anika Therapeutics, AInc. ~~Huss~~(“Anika”) asunder awhich ~~Class I director~~we onobtained ~~September 28,~~an ~~2007~~exclusive right to ~~serve~~market ~~for~~and asell ~~three~~Anika’s FDA-approved ~~year~~Elevess® ~~term~~temporary ~~until~~dermal ~~the~~filler ~~annual~~product ~~meeting~~in ~~of stockholders~~the inUnited ~~2010~~States. ~~The~~Elevess ~~Board~~is ~~also~~a hyaluronic ~~elected~~acid ~~Ms.~~(HA) ~~Huss~~based tofiller ~~the~~formulated ~~Nominating~~with ~~Committee~~Lidocaine for patient comfort and used for the ~~Compensation~~correction ~~Committee.~~of ~~Ms. Huss~~facial iswrinkles ~~currently~~and folds. Under the ~~President~~Agreement, ~~and~~Anika ~~Chief~~will ~~Executive~~manufacture ~~Officer~~and ofsupply ~~Vibrynt,~~Elevess ~~Inc~~to us., aWe ~~venture-backed~~will ~~medical~~pay ~~device~~Anika ~~company.~~a ~~Prior~~fixed toprice ~~joining~~per ~~Vibrynt~~unit, ~~Ms. Huss~~plus ~~served as~~ a ~~senior~~royalty ~~advisor~~based ~~for~~on ~~Pervasis~~net ~~Therapeutics,~~sales ~~Inc~~of Elevess., aThe ~~venture-backed~~initial ~~biotechnology~~term ~~company,~~of ~~from April 2005~~the toAgreement ~~January 2007.~~runs ~~From~~through ~~January~~December ~~2001~~31, ~~to January 2005~~2010, ~~Ms. Huss~~but ~~served~~we ashave ~~President~~an ~~of the~~option ~~Endovascular~~to ~~Solutions~~extend ~~division~~the ofterm ~~Guidant~~through ~~Corporation. Ms.~~December ~~Huss~~31, ~~also~~2012 ~~currently~~if ~~serves~~we onachieve ~~the board~~a ofsales ~~directors~~target ofand ~~Dade~~make ~~Behring,~~a ~~Inc~~one-time extension payment., We agreed to purchase a ~~public~~minimum ~~company~~amount inof ~~the~~Elevess ~~medical~~during ~~device~~each ~~and~~year ~~diagnostic testing~~of ~~industry~~the Agreement.

AtItem ~~the Nominating Committee’s recommendation, the Board elected Robert B~~9. ~~Sherman as a Class III director on October 2, 2007 to serve for a two year term until the annual meeting of stockholders in 2009~~01. ~~The~~Financial ~~Board~~Statements ~~also elected Mr. Sherman to the Nominating Committee, the Audit Committee~~ and ~~the Compensation Committee~~Exhibits. Mr. Sherman has been a member of the Pilot Group, LLC, a private equity firm located in New York, since 2005. Prior to joining the Pilot Group, Mr. Sherman served as President, Interactive Marketing at America Online, Inc. from 2002 to 2005. Prior to joining AOL, Mr. Sherman was President of Time Warner Cable Advertising Sales. He also formerly served as an Executive Vice President of the radio stations owned and operated by NBC Universal, Inc. and as Chief Executive Officer of Della Femina, Travisano, Sherman & Olken, an advertising agency.

~~Item 9.01~~(d) ~~Financial Statements and~~ Exhibits

(d) Exhibits


Exhibit No.		Description

99.1		Press Release, dated July 8, 2008, relating to the Distribution Agreement with Anika Therapeutics, Inc.

99.1		Press Release, dated October 1, 2007, announcing the election of Beverly A. Huss to the Company’s Board of Directors.
99.2		Press Release, dated October 3, 2007, announcing the election of Robert B. Sherman to the Company’s Board of Directors.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Dated: ~~October~~July 38, ~~2007~~2008


	ARTES MEDICAL, INC.
	By:	/s/ Karla R. Kelly
		Karla R. Kelly
		Chief Legal Officer, General Counsel and Corporate Secretary

EXHIBIT INDEX

Exhibit No.		Description
99.1		Press Release, dated October 1, 2007, announcing the election of Beverly A. Huss to the Company’s Board of Directors.
99.2		Press Release, dated October 3, 2007, announcing the election of Robert B. Sherman to the Company’s Board of Directors.

UNITEDTable STATES SECURITIESof AND EXCHANGE COMMISSION Contents

Item 5.02.Table Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Contents

Table of Contents

Filing Compare · ARTES MEDICAL INC